LB PharmaceuticalsCommon Stock Other Current Liabilities

The latest other current liabilities for LBRX is $19M as of June 2026. That compares with $2.5M in the prior-year period — up 656.7% year over year. Investors often review this figure alongside LB PharmaceuticalsCommon Stock's historical trend and sector peers before judging valuation or financial health.

Over the past year, LBRX's other current liabilities moved from $2.5M to $19M — a 656.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LB PharmaceuticalsCommon Stock's operating scale or balance-sheet position.

A other current liabilities figure of $19M for LBRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LBRX's other current liabilities ($19M), review year-over-year change from $2.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack LB PharmaceuticalsCommon Stock's other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.